Advertisement

U.S. markets close in 2 hours 9 minutes

S&P 500
3,894.09
+49.01(+1.27%)
Dow 30
31,291.29
+253.61(+0.82%)
Nasdaq
11,600.08
+238.23(+2.10%)
Russell 2000
1,769.58
+42.04(+2.43%)
Crude Oil
103.47
+4.94(+5.01%)
Gold
1,739.00
+2.50(+0.14%)

Advertisement

Schrödinger, Inc. (SDGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

32.09

+2.09

(+6.97%)

As of 01:50PM EDT. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	30.00
Open	29.87
Bid	32.08 x 1000
Ask	32.13 x 800
Day's Range	29.80 - 32.14
52 Week Range	20.71 - 76.81
Volume	356,155
Avg. Volume	697,266

Market Cap	2.337B
Beta (5Y Monthly)	1.20
PE Ratio (TTM)	N/A
EPS (TTM)	-1.90
Earnings Date	Aug 10, 2022 - Aug 15, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	64.38

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SDGR

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Schrodinger, Inc.
Analyst Report: CRISPR Therapeutics AGCRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Rating
Fair Value
Economic Moat
21 days agoMorningstar

All

Business Wire
Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor
NEW YORK, June 28, 2022--Schrödinger today announced FDA clearance of investigational new drug application for SGR-1505, a MALT1 inhibitor.
Simply Wall St.
When Will Schrödinger, Inc. (NASDAQ:SDGR) Become Profitable?
With the business potentially at an important milestone, we thought we'd take a closer look at Schrödinger, Inc.'s...
Business Wire
Schrödinger Convenes Global Educators For Second Annual Educator’s Day
NEW YORK, June 22, 2022--Schrödinger convenes global educators for second annual Educator’s Day.

Advertisement

S&P 5003,894.09+49.01(+1.27%)

Dow 3031,291.29+253.61(+0.82%)

Nasdaq11,600.08+238.23(+2.10%)

Russell 20001,769.58+42.04(+2.43%)

Crude Oil103.47+4.94(+5.01%)

Gold1,739.00+2.50(+0.14%)

Schrödinger, Inc. (SDGR)

Chart Events

Performance Outlook

Fair Value

Related Research

Schrödinger Announces FDA Clearance of Investigational New Drug Application for SGR-1505, a MALT1 Inhibitor

When Will Schrödinger, Inc. (NASDAQ:SDGR) Become Profitable?

Schrödinger Convenes Global Educators For Second Annual Educator’s Day

S&P 500
3,894.09
+49.01(+1.27%)

Dow 30
31,291.29
+253.61(+0.82%)

Nasdaq
11,600.08
+238.23(+2.10%)

Russell 2000
1,769.58
+42.04(+2.43%)

Crude Oil
103.47
+4.94(+5.01%)

Gold
1,739.00
+2.50(+0.14%)